New regimen for patients with lymphoma prolongs PFS by up to 28 months

Share This Post

12 Yue days, a study “The Lancet” published online, for CD30 -positive outer peripheral -cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone ( A + CHP ) Better than cyclophosphamide, doxorubicin, vincristine and prednisone ( CHOP ).

Steven Horwitz , MD, from the Memorial Sloan Kettering Cancer Center in New York City and colleagues conducted a double-blind, placebo-controlled, active-control phase 3 study involving 452 patients from 132 locations in 17 countries . These patients CD30- positive peripheral T- cell lymphoma without prior treatment . Patients with 1 : 1 random allocation ratio, accepts A + CHP or of CHOP , sustained 6 , or . 8 th 21 is day cycle.

The researchers found that the median progression-free survival ( PFS ) of the A + CHP group and the CHOP group were 48.2 and 20.8 months, respectively. The incidence of side effects was similar between the two groups, including febrile neutropenia ( 18 % and 15 %, respectively) and peripheral neuropathy ( 52 % and 55 %, respectively). Fatal adverse events occurred in 3 % and 4 % of patients, respectively.

In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy